Active Ingredient History
Margetuximab, sold under the brand name Margenza, is a chimeric IgG monoclonal antibody medication against HER2 used for the treatment of cancer. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (approved 2020)
Breast Neoplasms (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Cholangiocarcinoma (Phase 1)
Esophageal Neoplasms (Phase 2/Phase 3)
Hematologic Neoplasms (Phase 1)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 1)
Ovarian Neoplasms (Phase 1)
Small Cell Lung Carcinoma (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
Stomach Neoplasms (Phase 2/Phase 3)
Uterine Cervical Neoplasms (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue